2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines

Liver International

Volumn 32, Issue SUPPL. 1, 2012, Pages 2-8

  Calvaruso, Vincenza ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Acute HCV infection; Chronic hepatitis C; EASL; HCV RNA; Pegylated interferon alpha; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIPYRETIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEPATITIS C ANTIBODY; INTERLEUKIN 28B; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; THYROTROPIN; VIRUS RNA;

ACUPUNCTURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ANEMIA; ANTIBODY DETECTION; BLOOD TRANSFUSION; CANCER RISK; COMORBIDITY; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DNA POLYMORPHISM; DRUG ABUSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; DYSPNEA; ELASTOGRAPHY; FATIGUE; GENETIC POLYMORPHISM; GENOTYPE; GOLD STANDARD; HEMODIALYSIS PATIENT; HEMOGLOBINOPATHY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; INSULIN RESISTANCE; INTRAVENOUS DRUG ABUSE; IRRITABILITY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MEDICAL SOCIETY; METABOLIC DISORDER; MIXED INFECTION; MOLECULAR DIAGNOSIS; MONOTHERAPY; NEUTROPENIA; NEUTROPHIL COUNT; NON INVASIVE PROCEDURE; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEROLOGY; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; TATTOOING; TERATOGENICITY; THALASSEMIA MAJOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROXINE BLOOD LEVEL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIROLOGY; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; STANDARD OF CARE;

EID: 84855215941     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02703.x     Document Type: Review

References (43)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
4. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47: 1371-83.
5. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.
6. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-62.
7. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24: 3-8.
8. Thompson CJ, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007; 11: 1-206.
9. Chevaliez S, Pawlotsky JM. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol 2008; 22: 1031-48.
10. Poynard T, Ngo Y, Munteanu M, et al. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir Ther 2010; 15: 617-31.
11. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009; 16: 300-14.
12. Ge DL, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
13. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
14. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-74.
15. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
16. Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-21.
17. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-28.
18. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha 2b a randomized trial. Ann Intern Med 2009; 150: W97-528.
19. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 final results: high sustained virologic response among genotype1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus PegIntron/ribavirin. Hepatology 2010; 52: 430A.
20. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002; 347: 975-98.
21. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
22. Diago M, Shiffman ML, Bronowicki JP, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40 kDa) plus ribavirin. Hepatology 2010; 51: 1897-903.
23. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
24. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kD)/ribavirin therapy. Hepatology 2006; 43: 954-60.
25. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.
26. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
27. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-9.
28. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype- 1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
29. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-13.
30. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 353-67.
31. Harmatz P, Jonas MM, Kwiatkowski JL, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematol-Hematol J 2008; 93: 1247-51.
32. Peck-Radosavljevic M, Boletis J, Besisik F, et al. Low-dose peginterferon alfa-2a (40KD) is safe and produces a SVR in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol 2011; 9: 242-8.
33. Potthoff A, Wiegand J, Luth JB, et al. Superiority of standard interferon-alpha2b compared to pegylated interferon- alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol 2005; 63: 232-5.
34. Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of epatitis C virus in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2010; 18: 871-6.
35. Safdar K, Schiff ER. Alcohol and hepatitis C. Semin Liver Dis 2004; 24: 305-15.
36. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol 2008; 49: 625-33.
37. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
38. Wiegand J, Jackel E, Cornberg M, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40: 98-107.
39. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43: 250-6.
40. Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. J Hepatol 2005; 42: S108-14.
41. Dienstag JL. Management of hepatitis C - reply. Gastroenterology 2006; 131: 332-3.
42. Flisiak R, Parfieniuk A. Investigational drugs for hepatitis C. Expert Opin Invest Drugs 2010; 19: 63-75.
43. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.